“The reason why so few antibiotics are being developed is simple – the market is broken. In recent months, lawmakers on both sides of the aisle have come together to introduce important policies designed to spur the development of new antibiotics. However, to protect the American people from resistant superbugs, bold action is needed from Congress and the Administration to stimulate innovation and produce new antimicrobials that patients and society can count on.”
Jim Greenwood, Biotechnology Innovation Organization
Source: Ending the Cycle of Crisis and Complacency in U.S. Global Health Security – A Report of the CSIS Commission on Strengthening America’s Health Security
